Catecholaminergic polymorphic ventricular tachycardia (and seizure) caused by a novel homozygous likely pathogenic variant in CASQ2 gene

• Published in: Gene 2024-02, Vol.895, p.148012-148012, Article 148012
• Main Authors: Askarinejad, Amir, Esmaeili, Shiva, Dalili, Mohamad, Biglari, Alireza, Kohansal, Erfan, Maleki, Majid, Kalayinia, Samira
• Format: Article
• Language: English
• Subjects: Calsequestrin; Calsequestrin - genetics; CASQ2; CPVT; Death, Sudden, Cardiac; Genetic; Homozygote; Humans; Mutation; Seizures; Tachycardia, Ventricular - diagnosis; Tachycardia, Ventricular - genetics; Variant
• ISSN: 0378-1119; 1879-0038
• DOI: 10.1016/j.gene.2023.148012

Although structural heart disease is frequently present among patients who experience sudden cardiac death (SCD), inherited arrhythmia syndromes can also play an important role in the occurrence of SCD. CPVT2, which is the second-most prevalent form of CPVT, arises from an abnormality in the CASQ2 gene. We represent a novel CASQ2 variant that causes CPVT2 and conduct a comprehensive review on this topic. The proband underwent Whole-exome sequencing (WES) in order to ascertain the etiology of CPVT. Subsequently, the process of segregating the available family members was carried out through the utilization of PCR and Sanger Sequencing. We searched the google scholar and PubMed/Medline for studies reporting CASQ2 variants, published up to May 10,2023. We used the following mesh term “Calsequestrin” and using free-text method with terms including “CASQ2”,”CASQ2 variants”, and “CASQ2 mutation”. The CASQ2 gene was found to contain an autosomal recessive nonsense variant c.268_269insTA:p.Gly90ValfsTer4, which was identified by WES. This variant was determined to be the most probable cause of CPVT in the pedigree under investigation. CASQ2 variants play an important role in pathogenesis of CPVT2. Notabely, based on results of our study and other findings in the literature the variant in this gene may cause an neurological signs in the patients with CPVT2. Further studies are needed for more details about the role of this gene in CPVT evaluation, diagnosis, and gene therapy.